All In Biotech

Free tool

FAERS Monitor: Fetzima

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204168 or its brand name (Fetzima, Levomilnacipran Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,929

Serious

1,027

53% of reports

Hospitalization

320

Death reported

176

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use350
  • drug ineffective266
  • pain225
  • vomiting221
  • memory impairment205
  • hypoaesthesia198
  • abdominal pain upper196
  • paraesthesia192
  • gastrooesophageal reflux disease185
  • migraine183
  • drug intolerance177
  • epilepsy168
  • taste disorder168
  • blepharospasm167
  • nausea154

Reports by year received

View as table
YearReports
20131
2014142
2015214
2016307
2017224
2018123
2019174
2020100
2021112
2022122
2023111
202473
2025158
202668

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,230 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blepharospasmSignal167296.9256.347,676
taste disorderSignal16891.078.714,761
epilepsySignal16860.252.19,689
gastrooesophageal reflux diseaseSignal18525.121.94,266
migraineSignal18320.918.23,464
drug intoleranceSignal17720.017.43,187
memory impairmentSignal20516.314.32,942
hypoaesthesiaSignal19814.412.72,478
paraesthesiaSignal19213.311.62,190
abdominal pain upperSignal19610.49.11,668
vomitingSignal2215.14.5746
off label useSignal3504.44.0942
painSignal2254.03.5517
drug ineffectiveSignal2662.22.0185
nauseaSignal1542.11.894

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.